Close-up of a detailed anatomical eye model showcasing different parts for educational purposes.

Best Retina Specialist in Andheri, Mumbai — What “Best” Actually Means (A Patient’s Verification Guide)

/ Retina Services / By

Best Retina Specialist in Andheri, Mumbai — What “Best” Actually Means (A Patient’s Verification Guide)

Written & medically reviewed by Dr. Jignesh Gala, Vitreoretinal & Cataract Surgeon (FRCS Glasgow), Founder & Director — Crystal Clear Eye Clinic (Andheri West) and Topax Eye Hospital (Vile Parle East), Mumbai. Facts verified: 24 July 2026.

Thank you for reading this post, don't forget to subscribe!

⚡ Quick answer: “Best” is not an adjective a website can award itself — it is seven verifiable facts: genuine vitreoretinal fellowship, an international surgical qualification (FRCS/MRCS/FICO), an own operation theatre, on-site OCT, honest written outcomes, an emergency pathway, and a doctor who still reads current research. On all seven, Dr. Jignesh Gala — Dr Jignesh Gala, top eye specialist in Mumbai — passes with proof at Crystal Clear Eye Clinic, Andheri West and Topax Eye Hospital, Vile Parle East. Verify: 077188 85245.

🔎 Popular guides by Dr. Gala:

1. The 7-Point Checklist to Verify a Retina Specialist

Run these seven checks before you hand over your eyesight — they separate genuine sub-specialists from doctors who “also do retina.” (For non-retina problems, see the best eye specialist in Andheri Mumbai guide.)

  1. Vitreoretinal fellowship. An MS/DNB alone does not make a retina specialist. Ask where: L.V. Prasad or AIIMS means years of supervised retinal surgery.
  2. Sub-specialty focus. A doctor doing cataract Monday and “some retina” Wednesday cannot match someone whose daily work is maculas and detachments.
  3. Own operation theatre. Ask: “If I need urgent vitrectomy tonight, where does it happen?” A genuine surgeon has his own OT — not a borrowed slot.
  4. Research currency. Ten years ago geographic atrophy had no treatment; the GATHER2 phase-3 trial showed avacincaptad pegol slowing it (Lancet 2023), building on GATHER1 (Ophthalmology 2021). Ask what changed this year — the answer tells you everything.
  5. Honest written outcomes. The best retina specialist in Andheri states success and failure rates in writing — “primary detachment surgery succeeds in ~90% with one operation” is honest; “100% ho jayega” is not.
  6. Emergency access. Detachments don’t wait for OPD hours — a real retina practice has a same-day pathway and a surgeon who operates urgently.
  7. Language comfort. Retina diseases need lifelong follow-up. You must understand your own condition — Hindi, Marathi, Gujarati or English — not nod at jargon.
Best retina specialist in Andheri — retinal examination at Crystal Clear Eye Clinic, Andheri West, Mumbai
What “best” looks like: a dilated retinal examination at Crystal Clear Eye Clinic — every patient seen by the specialist himself.

2. Dr. Gala Against the Checklist — Point by Point, with Proof

We wrote the checklist, so we submit to it — the claim as verifiable facts:

Checklist PointDr. Jignesh Gala — The Verifiable Fact
Vitreoretinal fellowshipL.V. Prasad Eye Institute, Hyderabad — India’s most respected vitreoretinal training programme.
International qualificationsFRCS (Glasgow), MRCS (Edinburgh), FICO — among the world’s toughest surgical exit examinations.
Sub-specialty focusVitreoretina and cataract, daily. Founding ophthalmology team, Woodlands Health Singapore.
Own OT & equipmentOwn OT at Topax Eye Hospital, Vile Parle East; OCT/OCTA and laser at Crystal Clear Eye Clinic, Andheri West.
Research currencySix years as a BMJ Case Reports peer reviewer — fully aware of the latest research — unlike old practitioners who stopped reading journals years ago.
Honest written outcomesEvery surgical plan: outcomes, risks and alternatives in writing — yours to keep.
Emergency accessSame-day pathway for detachments and sudden vision loss; urgent vitrectomy in his own OT.
Language comfortEnglish, Hindi, Marathi, Gujarati — your OCT explained in your words.
Best retina specialist in Andheri West Mumbai — Dr Jignesh Gala examining retina with OCT review
Examination first, opinion second: Dr. Gala correlates the dilated examination with your OCT.

One more proof point: injection safety rests on published evidence — povidone-iodine asepsis prevents endophthalmitis (technique evidence), and protocol-driven high-volume clinics improve it further (clinic safety evidence). Dr. Gala runs his injection service on exactly these protocols. Full profile: best retina specialist Mumbai — Dr Jignesh Gala.

3. What a Full-Scope Retina Practice Covers in 2026

A genuine retina specialist covers the entire posterior segment — if your “retina doctor” sends you elsewhere for lasers or a macular hole, ask why:

ConditionFirst SymptomUsual Treatment (2026)
Diabetic retinopathy & macular edemaOften nothing, then patchy blurAnti-VEGF injections (₹8,000–38,000 by drug), PRP laser (₹3,000–8,000/sitting) — see our diabetic retinopathy specialist in Andheri West Mumbai
Wet AMDBent lines; central grey patchAnti-VEGF — aflibercept proven in the VIEW trials (VIEW evidence); Eylea injection cost & side effects (MRP ₹29,998 post April-2026 cut)
Dry AMD / geographic atrophySlow dimming of central visionMonitoring + complement inhibitors (avacincaptad pegol) where appropriate
PCV (polypoidal choroidal vasculopathy)Sudden central blur at 50–70Anti-VEGF ± PDT — aflibercept in the PLANET study (PLANET evidence)
Retinal detachmentFloaters, flashes, a curtainEmergency vitrectomy / buckle (₹50,000–1,50,000) — same day
Macular hole / epiretinal membraneCentral distortion, dark spotVitrectomy + membrane/ILM peel (₹45,000–1,20,000; vitrectomy ₹40,000–1,50,000)
Retinal vein occlusion (BRVO/CRVO)Sudden painless vision lossAnti-VEGF + laser; BP/sugar workup
High-myopia degenerationDistortion at −6 and aboveOCT monitoring; anti-VEGF if CNVM
Floaters & PVDDrifting black spots, cobwebsDilated check to rule out tears; laser/surgery in selected cases
Uveitis / retinal inflammationPain, redness, light sensitivitySteroid/immunosuppressive therapy, infection workup

Once your retina is stable, the same campus covers the rest of the family: Contoura LASIK in Mumbai, a guide to the best vision correction surgery after 40, glaucoma treatment in Andheri Mumbai, a premier pediatric ophthalmologist in Andheri Mumbai, and seasonal tips like how to prevent dry eyes in winter.

4. Red Flags When Choosing

  • 🚩 The “visiting-only” surgeon. He operates Tuesday, flies out — who handles your bleed Thursday night? Retina needs an on-call surgeon.
  • 🚩 No OCT on site. Sending you to a lab for every scan means days-old reports — retina decisions happen on today’s OCT, in the same room.
  • 🚩 No emergency pathway. Ask: “If I see a curtain tonight, what happens?” If the answer is “come Monday,” leave — detachments are measured in hours.
  • 🚩 100% guarantees. No honest surgeon guarantees outcomes in biological tissue — “100% result” is selling, not practising.
  • 🚩 Price opacity. We publish ranges (verified 24 July 2026): consultation ₹800–1,500, OCT ₹1,500–3,000/eye, OCTA ₹3,500–5,000 — call for exact pricing.
  • 🚩 The report you never see. Your scans belong to you — a specialist who won’t show your own OCT is hiding your data.

A fair test: take this checklist to any clinic — including ours. Verified facts are the only honest way to be called the best retina specialist in Andheri. More reading: the blogs by Dr Jignesh Gala.

5. Why Patients Call Dr. Gala the Best Retina Specialist in Andheri

Best retina specialist in Andheri — Dr Jignesh Gala, FRCS Glasgow, Crystal Clear Eye Clinic Mumbai
Dr. Jignesh Gala, FRCS (Glasgow) — L.V. Prasad vitreoretinal fellowship

Patients from Andheri West, Lokhandwala, Versova, Yari Road, Oshiwara, DN Nagar and Seven Bungalows choose Dr. Jignesh Gala for one reason: verification passes. FRCS (Glasgow), MRCS (Edinburgh), FICO; L.V. Prasad fellowship; Woodlands Health Singapore; B.Y.L. Nair Hospital; six years a BMJ Case Reports peer reviewer.

✅ He owns what he uses — the OT for your emergency vitrectomy is his OT; the OCT guiding your injection is in his clinic.

✅ Fully aware of the latest research — unlike old practitioners who stopped reading journals years ago: from GATHER2 to injection-safety protocols, current evidence shapes current decisions.

✅ He writes the plan down — diagnosis, options, success rates, costs, and what happens if we do nothing — in your language.

✅ He answers his own emergencies — same-day retina pathway, one number: 077188 85245.

6. Locations — Andheri West & Vile Parle East

1) Crystal Clear Eye Clinic — Andheri West

📍 Address: Laram Centre CHS, A1-202, Swami Vivekanand Road, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 • Open daily, closes 9 pm
📞 077188 85245 • 💬 WhatsApp Us
💳 Third-party/TPA cashless is done through Crystal Clear Eye Clinic (Andheri West).

Minutes from Lokhandwala, Versova, Yari Road, Juhu, Oshiwara, DN Nagar, Seven Bungalows, Azad Nagar, Veera Desai Road, Amboli and Jogeshwari; from Bandra, Khar, Santacruz, Goregaon, Malad and Kandivali, 20–30 minutes.

Best retina specialist in Andheri West — Crystal Clear Eye Clinic and Topax Eye Hospital team, Mumbai
One team, two centres — both led by Dr. Gala.

2) Topax Eye Hospital — Vile Parle East

📍 Vile Parle East, Mumbai • 📞 077188 85245 • Open daily, closes 9 pm
💳 Direct cashless is done through Topax Eye Care (Vile Parle East).

Convenient for Vile Parle East/West, Santacruz East, Khar, Bandra East, Kalina and the airport corridor — injections, lasers, vitrectomy and detachment surgery happen here, in Dr. Gala’s own theatre. Direct cashless is done through Topax Eye Care (Vile Parle East); third-party/TPA cashless is done through Crystal Clear Eye Clinic (Andheri West). See cashless eye surgery in Mumbai with Dr Jignesh Gala.

7. हिंदी • मराठी • ગુજરાતી — Patient Summaries

🇮🇳 हिंदी सारांश — अंधेरी में बेस्ट रेटिना स्पेशलिस्ट कैसे चुनें

अंधेरी में बेस्ट रेटिना स्पेशलिस्ट वही है जो 7 बातें साबित करे: रेटिना फेलोशिप, FRCS डिग्री, खुद का ऑपरेशन थियेटर, क्लीनिक में OCT, लिखित ईमानदार रिपोर्ट, इमरजेंसी सुविधा और आपकी भाषा में समझाना। डॉ. जिग्नेश गाला (FRCS ग्लासगो, L.V. प्रसाद फेलोशिप) सातों पर खरे उतरते हैं — Crystal Clear Eye Clinic, अंधेरी वेस्ट व Topax Eye Hospital, विले पार्ले ईस्ट में। अपॉइंटमेंट: 077188 85245।

🚩 मराठी सारांश — अंधेरीतील सर्वोत्तम रेटिना तज्ज्ञ कोण?

अंधेरीत बेस्ट रेटिना स्पेशलिस्ट निवडताना ७ गोष्टी तपासा: रेटिना फेलोशिप, FRCS पदवी, स्वतःचे ऑपरेशन थिएटर, OCT सुविधा, लेखी प्रामाणिक अहवाल, आपत्कालीन उपचार आणि तुमच्या भाषेत समजावणे. डॉ. जिग्नेश गाला (FRCS ग्लासगो, L.V. प्रसाद फेलोशिप) या सर्व निकषांवर उतरतात — Crystal Clear Eye Clinic, अंधेरी वेस्ट व Topax Eye Hospital, विले पार्ले ईस्ट येथे. भेटीसाठी: 077188 85245.

🟡 ગુજરાતી સારાંશ — અંધેરીમાં શ્રેષ્ઠ રેટિના સ્પેશિયાલિસ્ટ કોણ?

અંધેરીમાં બેસ્ટ રેટિના સ્પેશિયાલિસ્ટ પસંદ કરતાં 7 બાબતો ચકાસો: રેટિના ફેલોશિપ, FRCS ડિગ્રી, પોતાનું ઓપરેશન થિયેટર, ક્લિનિકમાં OCT, લખીત પ્રામાણિક અહેવાલ, ઈમર્જન્સી સુવિધા અને તમારી ભાષામાં સમજૂતી. ડૉ. જિગ્નેશ ગાલા (FRCS ગ્લાસગો, L.V. પ્રસાદ ફેલોશિપ) આ બધા માપદંડો પૂરા કરે છે — Crystal Clear Eye Clinic, અંધેરી વેસ્ટ અને Topax Eye Hospital, વિલે પારલે ઇસ્ટ ખાતે. એપોઈન્ટમેન્ટ: 077188 85245.

Best retina specialist in Andheri Mumbai — Dr Jignesh Gala in surgical scrubs at Topax Eye Hospital
Dr. Gala in theatre — emergencies and planned retina surgery alike happen in his own OT. Appointments: 077188 85245.

8. ❓ Frequently Asked Questions (English + Hinglish)

1. Best retina specialist kaise choose karein Andheri mein?

7 baatein verify karein: vitreoretinal fellowship, FRCS/MRCS/FICO qualifications, khud ka operation theatre, clinic mein OCT, likhit outcomes aur risks, same-day emergency access, aur aapki bhasha mein report samjhana. Dr. Gala ko aap khud in 7 sawalon se test kar sakte hain: 077188 85245.

2. What qualifications should a retina specialist have?

At minimum: MS/DNB plus a 1–2 year vitreoretinal fellowship at a recognised institute. Stronger: international exit exams like FRCS (Glasgow), MRCS (Edinburgh), FICO. Dr. Gala holds all three, trained at L.V. Prasad Eye Institute, and was Assistant Professor at B.Y.L. Nair Hospital.

3. What is the consultation fee of a retina specialist in Andheri, Mumbai?

In 2026: consultation ₹800–1,500; OCT ₹1,500–3,000/eye; OCTA ₹3,500–5,000; visual field ₹750–1,600/eye. Anti-VEGF ₹8,000–38,000 by drug (Eylea MRP ₹29,998 after the April-2026 cut); vitrectomy ₹40,000–1,50,000. Verified 24 July 2026 — call 077188 85245 for exact pricing.

4. Do I need a referral to see a retina specialist?

No — book directly, no referral letter needed. Many patients come via their general eye doctor and we happily coordinate; but floaters, flashes, distortion, diabetes or sudden vision drop? Walk in or call directly. Emergencies are seen same day.

5. Retina specialist aur general eye doctor mein kya farak hai?

General ophthalmologist poori aankh dekhta hai — motiyabind, chashma, infection. Retina specialist sirf aankh ke peechle hisse ka super-specialist hai — extra fellowship aur din bhar wohi surgeries. Chashme ke liye general doctor kaafi; floaters, flashes, diabetes ya detachment ke liye seedha retina specialist — waqt hi nazr bachata hai.

6. How do I know my retina problem is serious?

Same-day emergencies: sudden new floaters, flashes of light, a curtain or shadow spreading across vision, or straight lines suddenly bending — these can mean a tear, detachment, haemorrhage or wet AMD, where hours matter. Stable old floaters still deserve one dilated check.

7. Best retina specialist kahan milega Andheri West mein?

Crystal Clear Eye Clinic — Laram Centre CHS, A1-202, Swami Vivekanand Road, above Sunil Jewellers, near NADCO Shopping Centre, Railway Colony, Andheri West, Mumbai 400058 — open daily, closes 9 pm. Ya Topax Eye Hospital, Vile Parle East. Ek hi number: 077188 85245. Lokhandwala, Versova, Juhu, Oshiwara, DN Nagar, Jogeshwari — sab se 10–20 minute.

8. Can I get a second opinion from Dr. Gala?

Yes — bring your OCT films and reports (we can repeat scans on our machines). You get a written second opinion: diagnosis, whether the advised treatment is right, alternatives and honest success rates. Many confirm their surgery; a few discover they never needed it. Call 077188 85245.

Every guide below is written by the same surgeon who would operate on you:

From drjigneshgalaeye.com

From crystalcleareye.in

Your retina deserves a specialist. Today, not someday.

Choosing a retina specialist is a 10-year decision — your follow-ups, your injections, your emergencies all live with this one doctor. Verify the checklist, then book.

📍 Andheri West: Laram Centre CHS, A1-202, S.V. Road, above Sunil Jewellers, near NADCO Shopping Centre, Mumbai 400058
📍 Vile Parle East: Topax Eye Hospital • Open daily, closes 9 pm

📞 Call 077188 85245 💬 WhatsApp Us

Dr. Jignesh Gala, FRCS (Glasgow) — Vitreoretinal & Cataract Surgeon • drjigneshgalaeye.com • crystalcleareye.in

Medical disclaimer: This page is educational and does not replace a personal consultation. Prices are indicative, verified on 24 July 2026, and may change. Every eye is different — decisions are made only after examination by Dr. Jignesh Gala.

Research & Evidence Library — 181 Verified References

Every link verified live in July 2026 (official NCBI E-utilities). This is the research Dr. Gala reads — click any title to verify the science yourself.

IVT: Intravitreal Injection Technique & Safety

  1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. — Ophthalmology, 2012
  2. Intravitreal Injection–Technique and Safety. — Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2015
  3. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. — Lancet (London, England), 2023
  4. Improving Patient Safety in a High-Volume Intravitreal Injection Clinic. — Ophthalmology. Retina, 2022
  5. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. — JAMA ophthalmology, 2018
  6. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. — Ophthalmology, 2021
  7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. — Ophthalmology, 2020
  8. Assessment of the safety of intravitreal injection of metoprolol tartrate in rabbits. — Documenta ophthalmologica. Advances in ophthalmology, 2021

IVT: Endophthalmitis After Intravitreal Injection

  1. Endophthalmitis. — Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2013
  2. Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious. — Archivos de la Sociedad Espanola de Oftalmologia, 2023
  3. Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review. — Eye (London, England), 2018
  4. Sterile endophthalmitis after intravitreal injection of triamcinolone acetonide: case report and literature review. — Romanian journal of ophthalmology, 2024
  5. Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. — JAMA ophthalmology, 2025
  6. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. — Ophthalmic surgery, lasers & imaging retina, 2014
  7. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. — European journal of ophthalmology, 2021
  8. Endophthalmitis Incidence after Intravitreal Injection of Anti-VEGF Agents with Povidone-Iodine versus Aqueous Chlorhexidine Antisepsis. — Ophthalmology. Retina, 2025

IVT: Intravitreal Injection Pain, Anxiety & Anesthesia

  1. Topical anesthesia for intravitreal injection. — Expert opinion on drug delivery, 2012
  2. Cooling Anesthesia for Intravitreal Injections – A Review. — Clinical ophthalmology (Auckland, N.Z.), 2023
  3. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. — Psychology, health & medicine, 2015
  4. Effects of music therapy on intravitreal injections: a randomised clinical trial. — Singapore medical journal, 2025
  5. Anesthesia for Intravitreal Injection: A Systematic Review. — Clinical ophthalmology (Auckland, N.Z.), 2020
  6. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. — European journal of ophthalmology, 2006
  7. Patient pain during intravitreal injections under topical anesthesia: a systematic review. — International journal of retina and vitreous, 2017
  8. Pain control and subconjunctival haemorrhage after intravitreal injection using cooled anaesthetic eyedrops and antiseptics: A prospective, double-blind, randomized controlled trial. — Acta ophthalmologica, 2024

IVT: Ranibizumab For Diabetic Macular Edema

  1. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. — Survey of ophthalmology, 2023
  2. Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes. — Developments in ophthalmology, 2017
  3. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. — Ophthalmology. Retina, 2020
  4. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. — International journal of molecular sciences, 2022
  5. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. — Advances in therapy, 2023
  6. Diabetic macular edema. — Developments in ophthalmology, 2010
  7. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials. — Retina (Philadelphia, Pa.), 2014
  8. Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis. — JAMA ophthalmology, 2025

IVT: Aflibercept For Diabetic Macular Edema

  1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. — Ophthalmology, 2024
  2. IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. — Retina (Philadelphia, Pa.), 2025
  3. Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis. — European journal of ophthalmology, 2024
  4. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. — Ophthalmology, 2016
  5. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. — Current opinion in ophthalmology, 2025
  6. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. — Ophthalmology, 2026
  7. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. — Lancet (London, England), 2024
  8. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. — The New England journal of medicine, 2022

IVT: Faricimab (Vabysmo) Trials

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. — Lancet (London, England), 2022
  2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. — Ophthalmology, 2024
  3. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. — Lancet (London, England), 2022
  4. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. — Ophthalmology, 2026
  5. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. — Ophthalmology, 2019
  6. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. — Ophthalmology, 2024
  7. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. — Ophthalmology, 2025
  8. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. — Ophthalmology. Retina, 2025

IVT: Aflibercept 8 Mg (Photon / Pulsar)

  1. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. — Ophthalmology and therapy, 2025
  2. A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. — Ophthalmic research, 2026
  3. Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. — Ophthalmology and therapy, 2025
  4. Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. — Ophthalmology and therapy, 2026
  5. A Response to: Letter to the Editor Regarding “Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”. — Ophthalmology and therapy, 2026
  6. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. — JAMA ophthalmology, 2023
  7. High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? — Life (Basel, Switzerland), 2025
  8. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series. — BMC ophthalmology, 2024

IVT: Brolucizumab

  1. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. — Ophthalmology, 2021
  2. Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor? — Ocular immunology and inflammation, 2022
  3. [Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies]. — Vestnik oftalmologii, 2024
  4. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. — Retina (Philadelphia, Pa.), 2023
  5. EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION. — Retinal cases & brief reports, 2023
  6. Retinal vasculitis after intravitreal injection of brolucizumab. — Canadian journal of ophthalmology. Journal canadien d’ophtalmologie, 2022
  7. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. — Ophthalmology, 2020
  8. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. — Journal of vitreoretinal diseases, 2021

IVT: Ranibizumab Biosimilars

  1. Approved biosimilar ranibizumab-a global update. — Eye (London, England), 2023
  2. Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. — Ophthalmology and therapy, 2022
  3. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? — Eye (London, England), 2023
  4. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. — Journal of vitreoretinal diseases, 2025
  5. Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study). — Eye (London, England), 2024
  6. Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review. — Ophthalmology and therapy, 2021
  7. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. — Eye (London, England), 2024
  8. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence. — Ophthalmology and therapy, 2022

IVT: Anti-Vegf For Neovascular Amd

  1. VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. — International journal of molecular sciences, 2025
  2. Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. — Eye (London, England), 2024
  3. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. — Science translational medicine, 2022
  4. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. — Progress in retinal and eye research, 2021
  5. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration]. — Vestnik oftalmologii, 2017
  6. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. — Eye (London, England), 2025
  7. Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems. — International journal of pharmaceutics, 2024
  8. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. — Biomolecules, 2024

IVT: Retinal Vein Occlusion Anti-Vegf

  1. Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies. — Diagnostics (Basel, Switzerland), 2024
  2. [Retinal vein occlusion: anti-VEGF treatments]. — Journal francais d’ophtalmologie, 2009
  3. Retinal Vein Occlusion. — Developments in ophthalmology, 2016
  4. Use of Anti-VEGF Drugs in Retinal Vein Occlusions. — Current drug targets, 2020
  5. Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials. — Survey of ophthalmology, 2025
  6. Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion. — Ophthalmic epidemiology, 2021
  7. Retinal vein occlusion. — Handbook of clinical neurology, 2026
  8. Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis. — Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2024

IVT: Myopic Choroidal Neovascularization

  1. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. — Expert opinion on drug safety, 2022
  2. IMI Pathologic Myopia. — Investigative ophthalmology & visual science, 2021
  3. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. — Drugs, 2016
  4. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook. — Expert opinion on biological therapy, 2016
  5. Ranibizumab for myopic choroidal neovascularization. — Expert opinion on biological therapy, 2020
  6. Anti-VEGF Therapy in Myopic CNV. — Current drug targets, 2021
  7. Pharmacotherapy of Myopic Choroidal Neovascularization. — Current pharmaceutical design, 2018
  8. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. — PloS one, 2022

IVT: Proliferative Diabetic Retinopathy: Anti-Vegf Vs Prp

  1. Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis. — Ophthalmology. Retina, 2025
  2. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. — JAMA ophthalmology, 2024
  3. Diabetic retinopathy. — Nature reviews. Disease primers, 2016
  4. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. — JAMA, 2015
  5. A review of neovascular glaucoma. Etiopathogenesis and treatment. — Romanian journal of ophthalmology, 2021
  6. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review. — Survey of ophthalmology, 2021
  7. Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis. — Health technology assessment (Winchester, England), 2024
  8. [Diabetic retinopathy]. — Klinische Monatsblatter fur Augenheilkunde, 2021

IVT: Dexamethasone Implant (Ozurdex)

  1. Reverse engineering the Ozurdex dexamethasone intravitreal implant. — International journal of pharmaceutics, 2023
  2. Dexamethasone intravitreal implant (OZURDEX(®)) for macular edema secondary to noninfectious uveitis: a review of the literature. — Therapeutic delivery, 2019
  3. OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis: A Case-Based Discussion. — Retina (Philadelphia, Pa.), 2019
  4. Intraoperative Dexamethasone Intravitreal Implant (Ozurdex) in Vitrectomy Surgery for Epiretinal Membrane. — Current eye research, 2020
  5. CASE REPORT OF ABIOTROPHIA DEFECTIVA ENDOPHTHALMITIS AFTER REPEATED INJECTIONS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). — Retinal cases & brief reports, 2022
  6. PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX). — Retina (Philadelphia, Pa.), 2020
  7. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. — Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2014
  8. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. — Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016

IVT: Port Delivery System / Susvimo / Sustained Delivery

  1. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. — JAMA ophthalmology, 2025
  2. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. — Ophthalmology, 2022
  3. Ranibizumab port delivery system: a clinical perspective. — BMJ open ophthalmology, 2022
  4. Port Delivery System With Ranibizumab: As Always – Risks Versus Benefits for the Recipients. — Ophthalmic surgery, lasers & imaging retina, 2022
  5. Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. — Current opinion in ophthalmology, 2022
  6. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. — Expert opinion on biological therapy, 2022
  7. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. — Lancet (London, England), 2024
  8. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. — JAMA ophthalmology, 2025

IVT: Treat-And-Extend Anti-Vegf

  1. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. — Eye (London, England), 2023
  2. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. — Retina (Philadelphia, Pa.), 2015
  3. Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial. — JAMA ophthalmology, 2024
  4. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. — Eye (London, England), 2023
  5. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. — Vision (Basel, Switzerland), 2019
  6. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. — Ophthalmology and therapy, 2017
  7. The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. — International journal of molecular sciences, 2022
  8. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. — Drug design, development and therapy, 2022

IVT: Intravitreal Injection Real-World India

  1. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. — Clinical ophthalmology (Auckland, N.Z.), 2022
  2. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. — Ophthalmology and therapy, 2021
  3. REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema – RETORT study. — International journal of retina and vitreous, 2023
  4. “Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema”. — International journal of retina and vitreous, 2025
  5. Real-world experience of brolucizumab in nAMD. — Indian journal of ophthalmology, 2024
  6. Real-world outcomes of intravitreal anti-vascular endothelial growth factor monotherapy in proliferative type 2 macular telangiectasia. — Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021
  7. Ranizurel safety evaluation in real-world -(RaSER) study. — American journal of ophthalmology case reports, 2022
  8. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. — Indian journal of ophthalmology, 2024

IVT: Ocular Gene Therapy (Retina)

  1. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. — Lancet (London, England), 2017
  2. Lipid nanoparticles for gene therapy in ocular diseases. — Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2023
  3. Gene therapy for ocular angiogenesis. — Clinical science (London, England : 1979), 2003
  4. Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. — Cellular reprogramming, 2023
  5. Gene Editing for CEP290-Associated Retinal Degeneration. — The New England journal of medicine, 2024
  6. Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina. — Proceedings of the National Academy of Sciences of the United States of America, 2024
  7. Ocular Gene Therapy-The Future Is Now. — Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2016
  8. Minicircle Delivery to the Neural Retina as a Gene Therapy Approach. — International journal of molecular sciences, 2022

IVT: Pmc Free Full-Text (Intravitreal Anti-Vegf Reviews & Related)

  1. Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab. — Clinics (Sao Paulo, Brazil), 2012
  2. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). — Transactions of the American Ophthalmological Society, 2008
  3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. — Advances in therapy, 2020
  4. Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy. — Polymers, 2022
  5. One-Year Effectiveness Study of Intravitreously Administered Conbercept(®) Monotherapy in Diabetic Macular Degeneration: A Systematic Review and Meta-Analysis. — Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020
  6. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. — Clinical ophthalmology (Auckland, N.Z.), 2010
  7. The evolving therapeutic landscape of diabetic retinopathy. — Expert opinion on biological therapy, 2023
  8. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. — The Cochrane database of systematic reviews, 2019

OCT: Diabetic Macular Edema Biomarkers

  1. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers — Survey of ophthalmology, 2024
  2. Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis — Ophthalmology, 2026

OCT: Oct Angiography In Diabetic Retinopathy

  1. OCT angiography 2023 update: focus on diabetic retinopathy — Acta diabetologica, 2024
  2. New insights into diabetic retinopathy by OCT angiography — Diabetes research and clinical practice, 2018
  3. Optical coherence tomography angiography in diabetic retinopathy: an updated review — Eye (London, England), 2021

OCT: Glaucoma – Retinal Nerve Fiber Layer

  1. Retinal Nerve Fiber Layer Optical Texture Analysis: Involvement of the Papillomacular Bundle and Papillofoveal Bundle in Early Glaucoma — Ophthalmology, 2022
  2. Anatomical compensation of retinal nerve fiber layer improves the detection of glaucoma between ethnicities — Annals of the New York Academy of Sciences, 2024
  3. Racial Differences in Diagnostic Accuracy of Retinal Nerve Fiber Layer Thickness in Primary Open-Angle Glaucoma — American journal of ophthalmology, 2024

OCT: Telemedicine / Screening For Diabetic Retinopathy

  1. Review of smartphone funduscopy for diabetic retinopathy screening — Survey of ophthalmology, 2024
  2. Comparison of Telemedicine Screening of Diabetic Retinopathy by Mydriatic Smartphone-Based vs Nonmydriatic Tabletop Camera-Based Fundus Imaging — Journal of vitreoretinal diseases, 2021
  3. The role of tele-ophthalmology in diabetic retinopathy screening — Journal of optometry, 2020

OCT: Artificial Intelligence In Oct Interpretation

  1. [OCT biomarkers in diabetic maculopathy and artificial intelligence] — Die Ophthalmologie, 2024
  2. Artificial intelligence for retinal diseases — Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2024
  3. Artificial Intelligence and Imaging Processing in Optical Coherence Tomography and Digital Images in Uveitis — Ocular immunology and inflammation, 2022

OCT: Macular Hole & Epiretinal Membrane

  1. Epiretinal membrane: an overview and update — Japanese journal of ophthalmology, 2024
  2. In-Depth Analysis of Preoperative OCT Markers as Prognostic Factors for Lamellar Macular Holes and Epiretinal Membrane Foveoschisis — Ophthalmology. Retina, 2024
  3. Macular hole with epiretinal proliferation: diagnostic value of en-face optical coherence tomography and clinical characteristics — Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024

OCT: Central Serous Chorioretinopathy

  1. Central serous chorioretinopathy and the sclera: what we have learned so far — Japanese journal of ophthalmology, 2024
  2. Can we classify central serous chorioretinopathy better? Yes we can — Eye (London, England), 2022
  3. Diagnostic accuracy of OCT angiography for macular neovascularization in central serous chorioretinopathy: A systematic review and meta-analysis — Acta ophthalmologica, 2024

OCT: Age-Related Macular Degeneration Biomarkers

  1. OCT Prognostic Biomarkers for Progression to Late Age-related Macular Degeneration: A Systematic Review and Meta-analysis — Ophthalmology. Retina, 2024
  2. Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis — Ophthalmology, 2025
  3. Choroidal biomarkers in age-related macular degeneration — Survey of ophthalmology, 2025

OCT: Vitreomacular Traction

  1. Vitreomacular traction – a review — Eye (London, England), 2025
  2. Vitreomacular traction in diabetic retinopathy — Japanese journal of ophthalmology, 2024
  3. Vitreomacular Traction Surgery from the DISCOVER Study: Intraoperative OCT Utility, Ellipsoid Zone Dynamics, and Outcomes — Ophthalmic surgery, lasers & imaging retina, 2021

OCT: Swept-Source Oct / Enhanced Depth Imaging Choroid

  1. Choroidal biomarkers — Indian journal of ophthalmology, 2018
  2. Enhanced depth imaging in swept-source optical coherence tomography: Improving visibility of choroid and sclera, a masked study — European journal of ophthalmology, 2020
  3. Choroidal imaging biomarkers — Survey of ophthalmology, 2019